BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 38627727)

  • 1. An exosome mRNA-related gene risk model to evaluate the tumor microenvironment and predict prognosis in hepatocellular carcinoma.
    Du Z; Han X; Zhu L; Li L; Castellano L; Stebbing J; Peng L; Wang Z
    BMC Med Genomics; 2024 Apr; 17(1):86. PubMed ID: 38627727
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Establishment and Evaluation of Exosomes-Related Gene Risk Model in Hepatocellular Carcinoma.
    Zhu L; Lou Y; Xiao Q; Wang L; Chen G; Yang W; Wang T
    Biochem Genet; 2024 Apr; 62(2):698-717. PubMed ID: 37405532
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comprehensive study based on exosome-related immunosuppression genes and tumor microenvironment in hepatocellular carcinoma.
    Yang Z; Li X; Pan C; Li Y; Lin L; Jin Y; Zheng J; Yu Z
    BMC Cancer; 2022 Dec; 22(1):1344. PubMed ID: 36550445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Construction of a risk score prognosis model based on hepatocellular carcinoma microenvironment.
    Zhang FP; Huang YP; Luo WX; Deng WY; Liu CQ; Xu LB; Liu C
    World J Gastroenterol; 2020 Jan; 26(2):134-153. PubMed ID: 31969776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of Exosome-Related Gene Risk Model to Evaluate the Tumor Immune Microenvironment and Predict Prognosis in Triple-Negative Breast Cancer.
    Qiu P; Guo Q; Yao Q; Chen J; Lin J
    Front Immunol; 2021; 12():736030. PubMed ID: 34659224
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterizing the key genes of COVID-19 that regulate tumor immune microenvironment and prognosis in hepatocellular carcinoma.
    Gao S; Zhang L; Wang H
    Funct Integr Genomics; 2023 Aug; 23(3):262. PubMed ID: 37540264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overweight/obesity-related transcriptomic signature as a correlate of clinical outcome, immune microenvironment, and treatment response in hepatocellular carcinoma.
    Feng NN; Du XY; Zhang YS; Jiao ZK; Wu XH; Yang BM
    Front Endocrinol (Lausanne); 2022; 13():1061091. PubMed ID: 36714595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification and Validation of a Novel Tumor Microenvironment-Related Prognostic Signature of Patients With Hepatocellular Carcinoma.
    Li R; Zhao W; Liang R; Jin C; Xiong H
    Front Mol Biosci; 2022; 9():917839. PubMed ID: 35847972
    [No Abstract]   [Full Text] [Related]  

  • 9. Establishment and validation of a novel lysosome-related gene signature for predicting prognosis and immune landscape in hepatocellular carcinoma.
    Li H; Li J; Qu X; Dai H; Liu J; Ma M; Wang J; Dong W; Wang W
    J Cancer Res Clin Oncol; 2023 Dec; 149(19):17543-17557. PubMed ID: 37903936
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A cellular senescence-related classifier based on a tumorigenesis- and immune infiltration-guided strategy can predict prognosis, immunotherapy response, and candidate drugs in hepatocellular carcinoma.
    Luo Y; Liu H; Fu H; Ding GS; Teng F
    Front Immunol; 2022; 13():974377. PubMed ID: 36458010
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differentially expressed liver exosome-related genes as candidate prognostic biomarkers for hepatocellular carcinoma.
    Zuo B; Kuai J; Long J; Bian J; Yang X; Yang X; Xun Z; Li Y; Sun H; Sang X; Zhao H
    Ann Transl Med; 2022 Aug; 10(15):817. PubMed ID: 36034976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic Value of Cancer-Associated Fibroblast-Related Gene Signatures in Hepatocellular Carcinoma.
    Dong W; Xie Y; Huang H
    Front Endocrinol (Lausanne); 2022; 13():884777. PubMed ID: 35733776
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic and Immunological Significance of the Molecular Subtypes and Risk Signatures Based on Cuproptosis in Hepatocellular Carcinoma.
    Tang X; Ren X; Huang T; Miao Y; Ha W; Li Z; Yang L; Mi D
    Mediators Inflamm; 2023; 2023():3951940. PubMed ID: 37124062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DNA damage repair-related gene signature for identifying the immune status and predicting the prognosis of hepatocellular carcinoma.
    Lu Y; Wang S; Chi T; Zhao Y; Guo H; Wang H; Feng L
    Sci Rep; 2023 Nov; 13(1):18978. PubMed ID: 37923899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value and potential mechanism of cellular senescence and tumor microenvironment in hepatocellular carcinoma: Insights from bulk transcriptomics and single-cell sequencing analysis.
    Qu C; Wu Q; Lu J; Li F
    Environ Toxicol; 2024 May; 39(5):2512-2527. PubMed ID: 38189188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Construction and validation of a novel lysosomal signature for hepatocellular carcinoma prognosis, diagnosis, and therapeutic decision-making.
    Chen J; Gao G; He Y; Zhang Y; Wu H; Dai P; Zheng Q; Huang H; Weng J; Zheng Y; Huang Y
    Sci Rep; 2023 Dec; 13(1):22624. PubMed ID: 38114725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A prognostic four-gene signature and a therapeutic strategy for hepatocellular carcinoma: Construction and analysis of a circRNA-mediated competing endogenous RNA network.
    Zhang HY; Zhu JJ; Liu ZM; Zhang YX; Chen JJ; Chen KD
    Hepatobiliary Pancreat Dis Int; 2024 Jun; 23(3):272-287. PubMed ID: 37407412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Five metastasis-related mRNAs signature predicting the survival of patients with liver hepatocellular carcinoma.
    Chen C; Liu YQ; Qiu SX; Li Y; Yu NJ; Liu K; Zhong LM
    BMC Cancer; 2021 Jun; 21(1):693. PubMed ID: 34116652
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic prediction and immune infiltration analysis based on ferroptosis and EMT state in hepatocellular carcinoma.
    Liu Z; Wang J; Li S; Li L; Li L; Li D; Guo H; Gao D; Liu S; Ruan C; Dang X
    Front Immunol; 2022; 13():1076045. PubMed ID: 36591279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The identification of N6-methyladenosine-related miRNAs predictive of hepatocellular carcinoma prognosis and immunotherapy efficacy.
    Zou R; Liu Y; Qiu S; Lu Y; Chen Y; Yu H; Zhu H; Zhu W; Zhu L; Feng J; Han J
    Cancer Biomark; 2023; 38(4):551-566. PubMed ID: 38007640
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.